How relatively likely are other endocrinopathies when comparing different classes of ICPIs?
- Patients on PD-1 inhibitors are about twice as likely to develop hypothyroidism as patients on ipilimumab.
- PD-1 inhibitor therapy is about five times more likely to cause hyperthyroidism compared with PD-L1 inhibitor therapy, but hypothyroidism rates are similar.
- Patients on ipilimumab are about five times more likely to develop hypophysitis compared with those on PD-1 inhibitor therapy alone, but those who are on a combination of these drugs are more than twice as likely to develop hypophysitis compared with those on ipilimumab alone.
